Research & Regulatory News

MARITIME: Where the Monthly Compound Is Being Tested

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

Maridebart cafraglutide is in a multi-trial Phase 3 programme under the MARITIME name, registered across obesity, obstructive sleep apnoea and heart failure indications. The heart failure trial alone enrols 5,056 participants.

Key facts

MARITIME-HF
NCT07037459, recruiting, n=5,056
MARITIME-OSA-2
NCT07226765, active not recruiting, n=250
MARITIME-3-J
NCT06987695, active not recruiting, n=279
Phase
3, all of the above
Registry checked
ClinicalTrials.gov, 21 November 2026
Phase 2 readout
NEJM, 4 September 2025
Authorisation
None (investigational)

What the programme covers

More than weight. The registered Phase 3 trials verified on ClinicalTrials.gov span obesity, obstructive sleep apnoea and heart failure with preserved or mildly reduced ejection fraction. A compound entering Phase 3 across three organ-system indications simultaneously is being developed as a metabolic agent from the outset.

The scale of the heart failure trial

MARITIME-HF, NCT07037459, is recruiting 5,056 participants. That is larger than most obesity trials in this field and comparable to a dedicated cardiovascular outcome programme. Enrolment on that scale is committed only where the endpoint requires it, which points to hard clinical events rather than a surrogate.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Why sleep apnoea appears here too

Obstructive sleep apnoea is strongly associated with obesity, and tirzepatide has already been studied in it. A second compound entering the same indication indicates the field regards it as an established rather than speculative extension of incretin pharmacology.

Why regional trials appear separately

MARITIME-3-J is a separate registration with 279 participants. Regional trials exist because regulators in some jurisdictions require data in their own populations, and because BMI thresholds and body composition differ enough that a global trial does not automatically answer a local question.

What Phase 3 breadth does not establish

Efficacy. A large multi-indication Phase 3 programme reflects a sponsor's assessment that Phase 2 justified the investment. Jastreboff and colleagues published that Phase 2 in the New England Journal of Medicine in September 2025. Compounds enter Phase 3 across several indications and fail, and the programme is the question rather than the answer.

Current status

Maridebart cafraglutide holds no marketing authorisation anywhere and is available only within registered clinical trials. Nothing supplied here is related to it, and no research material is an alternative to any investigational or licensed medicine.

Frequently asked questions

What indications is MariTide being tested in?

Obesity, obstructive sleep apnoea, and heart failure with preserved or mildly reduced ejection fraction, across registered Phase 3 trials.

Is it approved anywhere?

No. It is investigational and available only within registered clinical trials.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Research & Regulatory News articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.